Pirfenidone improves survival in IPF: results from a real-life study期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Pirfenidone improves survival in IPF: results from a real-life study

Authors:	George A. Margaritopoulos Athina Trachalaki Athol U. Wells Eirini Vasarmidi Eleni Bibaki George Papastratigakis Stathis Detorakis Nikos Tzanakis Katerina M. Antoniou

Affiliation:	1.Respiratory Medicine Department,University Hospital of Heraklion,Crete,Greece;2.Interstitial Lung Disease Unit,Royal Brompton Hospital,London,UK;3.Radiology Department,University Hospital of Heraklion,Crete,Greece

Abstract:	Background Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone’s effect on mortality and adverse events profile outside the restrictions of a clinical trial. Methods This is a retrospective observational intention to treat study of 82 consecutive IPF patients (UHH cohort). Results We observed a high 3-years survival rate of 73% without excluding patients who discontinued treatment for different reasons. The survival was compared to the survival of an IPF cohort from a tertiary referral center (RBH cohort). After exclusion of severe cases (DLcop?p?

Keywords:
本文献已被 SpringerLink 等数据库收录！